Elevance Health, Inc. (ELV)
(Delayed Data from NYSE)
$274.66 USD
-8.42 (-2.97%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $274.50 -0.16 (-0.06%) 7:58 PM ET
5-Strong Sell of 5 5
A Value F Growth F Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ELV 274.66 -8.42(-2.97%)
Will ELV be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ELV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ELV
Cigna to Report Q2 Earnings: Can Evernorth Offset Healthcare Weakness?
Can Humana Beat Q2 Earnings Estimates on Insurance Unit Strength?
ELV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Can Optum Support UnitedHealth's Profit Amid Industry Headwinds?
Medical Expenses Erode Centene's Bottom Line in Rare Q2 Earnings Miss
Company News for Jul 18, 2025
Other News for ELV
Thermo Fisher Scientific Inc Sees Significant Reduction in Eaton Vance Worldwide Health ...
UnitedHealth sets 2025 outlook below consensus amid rising medical costs
UnitedHealth stumbles on weak profit outlook, drags peers lower
UnitedHealth stumbles as annual profit outlook disappoints
UnitedHealth Stock Is A Strong Buy Amid Unfavorable Medical Trends (Upgrade)